MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Meridian Bioscience Company Profile (NASDAQ:VIVO)

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $21.50 (10.65% upside)

Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
Show:
DateFirmActionRatingPrice TargetActions
2/1/2016Canaccord GenuityReiterated RatingHold$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016William BlairReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Canaccord GenuityReiterated RatingHold$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Craig HallumBoost Price TargetBuy$21.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Craig HallumLower Price TargetBuy$22.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Canaccord GenuityLower Price TargetHold$19.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/27/2015Hilliard LyonsInitiated CoverageBuy$23.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Canaccord GenuityLower Price TargetHold$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2015Canaccord GenuityBoost Price TargetHold$19.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2015Canaccord GenuityReiterated RatingHold$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015Canaccord GenuitySet Price TargetHold$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/23/2015Craig HallumUpgradeHold -> Buy$19.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/2/2015Raymond JamesDowngradeMarket Perform -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Robert W. BairdDowngradeOutperform -> Neutral$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2014Cowen and CompanyLower Price Target$24.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/9/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha